Monthly Archives: August 2020

Pfizer / BioNTech COVID-19 vaccine continues to show strong effect in early stage study (NYSE: PFE)

Data from an ongoing phase 1/2 clinical trial evaluate three dose levels of Pfizer (NYSE: PFE) and partner BioNTech SEs (NASDAQ: BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-dependent increases in glycoprotein receptor-binding domain (RBD) -binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. …

Read More »